TITLE

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

AUTHOR(S)
Lebovitz, Harold E.; Kreider, Margaret; Freed, Martin I.
PUB. DATE
May 2002
SOURCE
Diabetes Care;May2002, Vol. 25 Issue 5, p815
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Objective: Troglitazone treatment has been associated with idiosyncratic hepatic reaction leading to hepatic failure and death in some patients. This raises questions regarding whether all thiazolidinediones or peroxisomal proliferator-activated receptor-gamma (PPAR-gamma) agonists are hepatotoxic and whether data from clinical trials are adequate to detect a signal of potentially serious drug-related hepatotoxicity. The purpose of this study was to assess whether the idiosyncratic liver toxicity reported with troglitazone is molecule-specific or a thiazolidinedione class effect, based on liver enzyme data collected prospectively during phase 2/3 clinical trials with rosiglitazone, a new, potent, and specific member of the thiazolidinedione class.Research Design and Methods: This is an analysis of liver function in type 2 diabetic patients at baseline and serially in 13 double-blind, 2 open-label active-controlled, and 7 open-label extension studies of rosiglitazone treatment conducted in outpatient centers throughout North America and Europe. The study comprised > 6,000 patients aged 30-80 years with type 2 diabetes. Patients underwent baseline liver function studies and were excluded from clinical trials if they had an alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase value 2.5 times greater than the upper limit of the reference range. The main outcome measures were liver enzyme levels, which were assessed at screening, at baseline, and every 4 weeks for the first 3 months of treatment and at 6- to 12-week intervals thereafter. Patients with at least one on-therapy ALT value >3 times the upper limit of the reference range were identified, and their case records examined in detail.Results: At baseline, 5.6% of the patients with type 2 diabetes (mean HbA(1c) 8.5-9.0%) had serum ALT values between 1.0 and 2.5 times the upper limit of the reference range. On antidiabetic therapy, most of those patients ( approximately 83%) had a decrease in ALT values, many into the normal range. The percentages of all patients with an on-therapy ALT value >3 times the upper limit of the reference range during double-blind and open-label treatment were as follows: rosiglitazone-treated 0.32%, placebo-treated 0.17%, and sulfonylurea-, metformin-, or insulin-treated 0.40%. The respective rates of ALT values >3 times the upper limit of the reference range per 100 person-years of exposure were 0.29, 0.59, and 0.64.Conclusions: No evidence of hepatotoxic effects was observed in studies that involved 5,006 patients taking rosiglitazone as monotherapy or combination therapy for 5,508 person-years. This is in keeping with hepatic data from clinical trials of another member of the class, pioglitazone, and in contrast to the clear evidence of hepatotoxic effects observed during the troglitazone clinical trial program. These findings suggest that the idiosyncratic liver toxicity observed with troglitazone is unlikely to be a thiazolidinedione or a PPAR-gamma agonist class effect. Poorly controlled patients with type 2 diabetes may have moderate elevations of serum ALT that will decrease with improved glycemic control during treatment with rosiglitazone or other antihyperglycemic agents.
ACCESSION #
6585474

 

Related Articles

  • The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Poulsen, Mikael KÆr; Henriksen, Jan Erik; Hother-Nielsen, Ole; Beck-Nielsen, Henning; Poulsen, Mikael Kjaer // Diabetes Care;Dec2003, Vol. 26 Issue 12, p3273 

    Objective: Type 2 diabetes is caused by reduced insulin secretion and insulin resistance in skeletal muscle and liver. We tested the combination therapy with insulin aspart, rosiglitazone, and metformin with the purpose of treating all three defects in order to test the hypothesis...

  • Erratum to: Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes. Ortega, Francisco; Mercader, Josep; Moreno-Navarrete, José; Sabater, Mónica; Pueyo, Neus; Valdés, Sergio; Ruiz, Bartomeu; Luche, Elodie; Serino, Matteo; Naon, Deborah; Ricart, Wifredo; Botas, Patricia; Delgado, Elias; Burcelin, Remy; Frühbeck, Gema; Bosch, Fatima; Mingrone, Gertrude; Zorzano, Antonio; Fernández-Real, José // Journal of Molecular Medicine;Apr2013, Vol. 91 Issue 4, p535 

    A correction to the article "Targeting the Association of Calgranulin B (S100A9) With Insulin Resistance and Type 2 Diabetes" that was published in the March 8, 2013 issue is presented.

  • Homeostasis Model Assessment as a Clinical Index of Insulin Resistance in Type 2 Diabetic Patients Treated With Sulfonylureas. Emoto, Masanori; Nishizawa, Yoshiki; Maekawa, Kiyoshi; Hiura, Yoshikazu; Kanda, Hiroyuki; Kawagishi, Takahiko; Shoji, Tetsuo; Okuno, Yasuhisa; Morii, Hirotoshi // Diabetes Care;May99, Vol. 22 Issue 5, p818 

    Presents information on a study which investigated whether homeostasis model assessment is associated with the insulin euglycemic-hyperinsulinemic clamp in a restrospective analysis in type two diabetic patients treated with sulfonylureas. Research design and methods; Results; Conclusions.

  • Treating Type 2 Diabetes Mellitus: A Growing Epidemic. Weinstock, Ruth S. // Mayo Clinic Proceedings;Apr2003, Vol. 78 Issue 4, p411 

    Editorial. Introduces articles published in the April 2003 issue of 'Mayo Clinic Proceedings' journal. Treatment of type-2 diabetes mellitus. Prevalence; Importance of early diagnosis for the initiation of aggressive treatment to prevent complications; Glycemic control; Insulin resistance.

  • Cinnamon: New Applications for An Old Spice. Hawkins, Ernest B. // Natural Pharmacy;Aug2004, Vol. 8 Issue 4, p12 

    Discusses the potential of cinnamon to help the response to insulin in type 2 diabetes. Role of cinnamon in Traditional Chinese Medicine; Regulation of blood sugar levels; Use of cinnamon oil to treat oral candidiasis in patients with acquired immune deficiency syndrome.

  • 7. Physical activity and type 2 diabetes mellitus.  // Journal of Endocrinology, Metabolism & Diabetes of South Africa;Jun2012, Vol. 17 Issue 2, pS18 

    The article discusses the importance of physical activity in the management of type 2 diabetes. It states that regular physical activity provides several benefits to diabetic patients including increased cardiorespiratory fitness, decreased insulin resistance and improved glycaemic control....

  • CLINICAL ROUNDS: Medications in Diabetes Management. Wilchowski, Sara; Waack, Stacy; Levine, Shel // Clinical Kinesiology (Online Edition);Winter2007, p25 

    No abstract available.

  • Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit. Papaetis, Georgios S.; Orphanidou, Dora; Panagiotou, Themistoklis N. // Current Drug Targets;Sep2011, Vol. 12 Issue 10, p1498 

    No abstract available.

  • Integrated lipidomics and transcriptomic analysis of peripheral blood reveals significantly enriched pathways in type 2 diabetes mellitus. Chen Zhao; Jinghe Mao; Junmei Ai; Ming Shenwu; Tieliu Shi; Daqing Zhang; Xiaonan Wang; Yunliang Wang; Youping Deng // BMC Medical Genomics;2013, Vol. 6 Issue Suppl 1, p1 

    Background: Insulin resistance is a key element in the pathogenesis of type 2 diabetes mellitus. Plasma free fatty acids were assumed to mediate the insulin resistance, while the relationship between lipid and glucose disposal remains to be demonstrated across liver, skeletal muscle and blood....

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics